Search Results
Aug 26, 2026, 09:05 ET HYDRINITY Accelerated Skin Science Expands Global Footprint Through Strategic Partnership in Scandinavia
technologies including Supercharged HA™, MicroFusion™, and RetaXome™. Founded as a regenerative medicine company developing advanced wound care and drug delivery systems for oncology and hematology patients, HYDRINITY has since redefined dermatological skincare with clinically backed formulations featuring
More news about: HYDRINITY Accelerated Skin Science
Aug 26, 2026, 09:00 ET ReviR Therapeutics Receives FDA Rare Pediatric Disease Designation for RTX-117 in Charcot-Marie-Tooth Disease
company advancing small-molecule therapies through the integration of artificial intelligence and RNA biology, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to RTX-117, the company's investigational oral small-molecule candidate,
More news about: ReviR Therapeutics
Aug 26, 2026, 09:00 ET Zifo Accelerates LIMS Master Data Validation with New AI-Enabled Services Accelerator
Prompt Management: Allows flexible, session-level configurations to accommodate different validation rules for various project types—from strict drug substance compliance to flexible in-house methods—without requiring code changes.Operating specifically within the Quality Control &
More news about: Zifo
Aug 26, 2026, 08:48 ET 4Sight Labs Expands OptiGuard™ to Cover Shared Cells with Up to Four Occupants
www.4sightlabs.com/SourcesU.S. Food and Drug Administration — 510(k) clearance documentation for radar-based vital-sign monitoring sensors intended for general-care hospital environments.Media
More news about: 4Sight Labs
Aug 26, 2026, 08:37 ET Mapping Smarter Drug Delivery for Treating Oral Cancers: A Hasanuddin University Review
Pharmacy, Hasanuddin University, Indonesia, suggests that conditions in the mouth can interfere with local drug delivery in oral squamous cell carcinoma (OSCC). "There is a tendency to think of drug delivery as a problem that can be solved by developing a better formulation. However, the bigger question
More news about: Hasanuddin University
Aug 26, 2026, 08:30 ET PrecisionLife Selects Gencove as US Partner to Launch and Deliver DNA Wellness Reports
drivers of disease that conventional approaches miss. PrecisionLife insights enable better disease understanding and patient stratification, accelerate drug development, and support more personalized healthcare and wellness solutions for chronic diseases affecting billions of lives.
More news about: Precisionlife Ltd
Aug 26, 2026, 08:02 ET Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays
BIOTECH:SignalChem Biotech, a wholly owned subsidiary of Sino Biological Inc. (SZSE: 301047), provides specialized reagents and CRO services supporting drug discovery and life science research. Sino Biological is an international life science tools provider with facilities across Asia, North America and
More news about: Sino Biological
Aug 26, 2026, 08:00 ET Ministry of Food and Drug Safety of Korea, Accelerates the Pace of Innovation for the Great Leap in Bio
Aug. 26, 2026 /PRNewswire/ -- This is an article published in The Korea Herald: The Ministry of Food and Drug Safety of Korea (MFDS, Minister Oh Yu-Kyoung) announced that it will host Global Bio Conference 2026 (GBC 2026) over three days from 26 August at the
More news about: The Korea Herald
Aug 26, 2026, 08:00 ET Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays
BIOTECH:SignalChem Biotech, a wholly owned subsidiary of Sino Biological Inc. (SZSE: 301047), provides specialized reagents and CRO services supporting drug discovery and life science research. Sino Biological is an international life science tools provider with facilities across Asia, North America and
More news about: Monod Bio
Aug 26, 2026, 07:54 ET DarwinHealth Introduces Quantum Cancer Biology: A Cell-State Systems Biology Framework for Precision Oncology
single tumor.Toward Rational Combination Therapy for CancerDrug resistance remains the leading cause of mortality in patients with advanced cancer.When one therapeutic agent successfully eliminates drug-sensitive cells, resistant populations frequently survive, expand, and ultimately
More news about: DarwinHealth
Aug 26, 2026, 07:00 ET Vivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for Mesothelioma
the safe to proceed for the Phase 3 sTEADfast clinical study from the FDA, VT3989 has also been granted both Fast Track and Orphan Drug designations by the U.S. Food and Drug Administration. With the new team capable of advancing VT3989 through late-stage development and toward commercialization, Vivace
More news about: Vivace Therapeutics, Inc.
Aug 26, 2026, 07:00 ET Insmed to Present at September 2026 Investor Conferences
mid- to late-stage investigational medicines — including two approved therapies to treat chronic, debilitating lung diseases — as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around
More news about: Insmed Incorporated
Aug 26, 2026, 07:00 ET Cigna Healthcare Connects Medical and Supplemental Benefits To Help People Better Manage Unexpected Health Costs
peace of mind that comes from knowing they're covered when an unexpected or costly health event occurs, especially as rising hospital and prescription drug costs, inflation and other financial pressures continue to strain household budgets," said Bryan Holgerson, President, Cigna Healthcare U.S. and
More news about: Cigna Healthcare
Aug 26, 2026, 07:00 ET HUMAN CLINICAL STUDY FINDS SOURSOP JUICE CONSUMPTION SIGNIFICANTLY LOWERS BLOOD PRESSURE AND SERUM URIC ACID
replacement for prescription blood-pressure or uric-acid-lowering medications, nor did the researchers directly compare soursop against a pharmaceutical drug. Instead, the research provides human clinical evidence supporting further investigation into the potential role of soursop as part of a health-conscious
More news about: SOPREME Soursop
Aug 26, 2026, 07:00 ET The J.M. Smucker Co. Announces Fiscal Year 2027 First Quarter Results and Updates Full-Year Fiscal 2027 Outlook
either the Company's products or its competitors' products, changes in consumer preferences, consumer or other litigation, actions by the U.S. Food and Drug Administration or other agencies, and product recalls; risks associated with derivative and purchasing strategies the Company employs to manage commodity
More news about: The J.M. Smucker Co.
Aug 26, 2026, 06:47 ET Alebund Pharmaceuticals Announces 2026 Interim Results
subsequent to the Reporting Period, the New Drug Application submitted by the Company for AP301 for the treatment of hyperphosphatemia in chronic kidney disease ("CKD") patients receiving maintenance dialysis was accepted for review by the NMPA as a Class 1 chemical drug in China.AP306 — the global
More news about: Alebund Pharmaceuticals
Aug 26, 2026, 06:45 ET Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
Lilly's current belief and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, access, and commercialization. Among other things, there can be no guarantee that future study results will be consistent with
More news about: Eli Lilly and Company
Aug 26, 2026, 06:37 ET Commercialization Roadmap Validated with Three-digit Million-dollar Revenue: Insilico Medicine Announces Interim Results for the First Half of 2026
Company announced that it further expanded its drug discovery collaboration with Tenacia Biotechnology, entering into a CNS drug R&D collaboration with a total deal value of US$94.75 million.In the Asia-Pacific region, where generative AI drug discovery innovations continue to bring changes,
More news about: Insilico Medicine
Aug 26, 2026, 06:00 ET Spineart and eCential Robotics receive FDA 510(k) clearance for the PERLA® TL application for use with eCential® Op.n® navigation system for robotic procedures.
2026 /PRNewswire/ -- Spineart, a global fast-growing company in spine surgery innovation, and eCential Robotics today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the PERLA® TL application (PERLA® by Spineart app) for use with the eCential® Op.n® Navigation
More news about: Spineart
Aug 26, 2026, 05:29 ET SK Biopharmaceuticals to In-License Epilepsy Drug Candidate 'Opakalim'
as indication expansion and formulation diversification. Early this year, the company submitted a New Drug Application (NDA) for an oral suspension formulation and is pursuing supplemental New Drug Applications (sNDAs) within the year to expand the label to include primary generalized tonic-clonic (PGTC)
More news about: SK Biopharmaceuticals. Co., Ltd.
Aug 26, 2026, 02:46 ET BioArctic: Interim Report for the period April - June 2026
agreement with Eli Lilly and Company regarding a potential new treatment combining BioArctic's proprietary BrainTransporter™-technology with an undisclosed drug candidate from Eli Lilly targeting neurodegeneration. As part of the agreement, BioArctic will receive an upfront payment of USD 30 million. The agreement
More news about: BioArctic
Aug 26, 2026, 02:43 ET BioArctic: Interim Report for the period April - June 2026
agreement with Eli Lilly and Company regarding a potential new treatment combining BioArctic's proprietary BrainTransporter™-technology with an undisclosed drug candidate from Eli Lilly targeting neurodegeneration. As part of the agreement, BioArctic will receive an upfront payment of USD 30 million. The agreement
More news about: BioArctic
Aug 26, 2026, 02:36 ET Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
expected in 2H 2026. Following the close of the transaction, the companies will collaborate to advance opakalim through development and U.S. Food and Drug Administration (FDA) approval, combining Biohaven's innovative Kv7 platform with SK Biopharmaceuticals' global development and regulatory capabilities
More news about: Biohaven Ltd.
Aug 26, 2026, 02:15 ET 4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing
manufacturing, combined with the growing demand we're seeing from drug developers for our DNA molecules, speaks to where this industry is heading where synthetic DNA is becoming a critical enabler of genetic medicine. 4basebio is focused on giving drug developers a manufacturing platform upon which they can confidently
More news about: Genezen
Aug 25, 2026, 21:24 ET Caliway's CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial; Pivotal Phase 3 Trial SUPREME-01 Initiates Enrollment
therapeutics, today announced two major clinical milestones in its new drug development program. The Investigational New Drug application for CBL-0201WR, a Phase 2 clinical trial combining its first-in-class local fat-reducing new drug CBL-514 with Eli Lilly's Zepbound® (Tirzepatide), has been cleared
More news about: Caliway Biopharmaceuticals